OncologyFDA Approved

Elagolix (Orilissa)

Oral

Overview

Elagolix is a small molecule non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist administered orally. While not a peptide itself, it mimics the antagonist action of peptide GnRH blockers by competitively inhibiting endogenous GnRH at pituitary receptors, resulting in dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and ovarian sex steroids.

Mechanism of Action

It is indicated for management of moderate to severe endometriosis pain and heavy menstrual bleeding associated with uterine fibroids. The oral bioavailability distinguishes it from injectable peptide GnRH antagonists..

Research Summary & Key Findings

Elagolix received FDA approval in 2018 for endometriosis and in 2020 (as part of a combination product) for uterine fibroids. The Elaris endometriosis trials (published in NEJG 2017) demonstrated significant reductions in dysmenorrhea and non-menstrual pelvic pain compared to placebo across two dose regimens. Phase 3 trials in uterine fibroids showed meaningful reductions in menstrual blood loss when combined with estradiol and norethindrone add-back therapy.

Clinical Status

FDA Approved

Elagolix (Orilissa) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Oral

Related Peptides in Oncology

Carfilzomib (Kyprolis)

FDA Approved

A tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...

View details

Bortezomib (Velcade)

FDA Approved

A modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortez...

View details

Lutetium-177 dotatate (Lutathera)

FDA Approved

A radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...

View details

Leuprolide (Lupron) - Oncology

FDA Approved

A GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in pre...

View details

Find a Provider

Find a verified provider who offers Elagolix (Orilissa) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Elagolix (Orilissa).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.